Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct-Dec;11(4):358-362.
doi: 10.4103/UA.UA_175_18.

Outcome of thulium laser enucleation of prostate surgery in high-risk patients with benign prostatic hyperplasia

Ketan P Vartak  1 , Kshitij Raghuvanshi  1
Affiliations

Outcome of thulium laser enucleation of prostate surgery in high-risk patients with benign prostatic hyperplasia

Ketan P Vartak et al. Urol Ann. 2019 Oct-Dec.

Abstract

Background: Benign prostatic hyperplasia (BPH) is one of the most common diseases in aging men and a significant cause of burden worldwide. Here, we report our experience of Thulium LASER enucleation of the prostate (ThuLEP) in high-risk patients with BPH.

Methods: This was a prospective study conducted between July 2011 and June 2016. The study participants were patients with a confirmed diagnosis of BPH, who required surgery, and were clinically eligible for ThuLEP.

Results: A total of 109 patients were included in the study. Of the total 109 patients, 82 patients had American Society of Anesthesiologists (ASA) Grade 3 and 27 had ASA Grade 4. The most common comorbidity was ischemic heart diseases (72.5%), followed by hypertension (57.8%) and diabetes mellitus (48.6%). During the procedure, a total of 11 (10.1%) patients had a fall in blood pressure requiring noradrenaline or mephentine and seven (6.4%) patients had early left ventricular failure. Sixteen (14.8%) patients had arrhythmias (benign) and seven (6.4%) patients with arrhythmias required antiarrhythmic drugs. The overall duration of surgery ranged from 55 to 70 min, laser time ranged from 25 to 35 min, hospital stay ranged from 30 to 36 h, and the mean catheter time was around 24 h. Overall, the change in hemoglobin ranged from 0.5 to 0.8 g/dL.

Conclusion: Results show that ThuLEP could be a better option in high-risk patients with BPH.

Keywords: Benign prostatic hyperplasia; enucleation; mortality; thulium laser.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367:248–57. - PubMed
    1. Braeckman J, Denis L. Management of BPH then 2000 and now 2016 – From BPH to BPO. Asian J Urol. 2017;4:138–47. - PMC - PubMed
    1. Ketan PV, Prashant HS. Thulium laser enucleation of the prostate is a safe and a highly effective modality for the treatment of benign prostatic hyperplasia – Our experience of 236 patients. Urol Ann. 2016;8:76–80. - PMC - PubMed
    1. Zhang F, Shao Q, Herrmann TR, Tian Y, Zhang Y. Thulium laser versus holmium laser transurethral enucleation of the prostate: 18-month follow-up data of a single center. Urology. 2012;79:869–74. - PubMed
    1. Bozzini G, Seveso M, Melegari S, de Francesco O, Buffi NM, Guazzoni G, et al. Thulium laser enucleation (ThuLEP) versus transurethral resection of the prostate in saline (TURis): A randomized prospective trial to compare intra and early postoperative outcomes. Actas Urol Esp. 2017;41:309–15. - PubMed